BackViracta Therapeutics Overview

Viracta Therapeutics Receivables

Latest receivables for VIRX: $0.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00
100.00% YoYΔ $-295000.00 vs prior year quarter

Peer average

Loading

Viracta Therapeutics Receivables History

Loading

Viracta Therapeutics vs. peers: Receivables Comparison

Loading

Viracta Therapeutics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Viracta Therapeutics (VIRX) FAQ

As of the most recent data (September 2024), VIRX shows a receivables of $0. That compares with $300K in the prior-year period — down 100.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, VIRX's receivables is now $0 (was $300K) — a 100.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Viracta Therapeutics is outperforming or lagging.

Tracking VIRX's receivables over time shows whether Viracta Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $0 That compares with $300K in the prior-year period — down 100.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Viracta Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $0) with ownership activity and broader fundamentals.

Viracta Therapeutics's receivables is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.